louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01650116: Evaluation of Hemodynamics and Amount of Blood Flowing Through the Kidneys During Liver Transplant by Measuring Some Physiological Substances in Blood and Urines
Official title: Evaluation of Sodium Urinary Excretion, Chlorine Urinary Excretion, Urinary Partial CO2 Pressure as Renal Perfusion Indicators During Liver Transplant. Comparison With Other Polemic State Indicators (Such as PiCCO, ScvO2, O2 Delivery).
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hypovolemia During Liver Transplantation
Renal Hypoperfusion During Liver Transplantation
Keywords: hypovolemia
renal hypoperfusion
liver transplantation
sodium
chloride
PuCO2
ScvO2
PiCCO
O2-delivery
hemodynamic indexes
Lead sponsor: Azienda Ospedaliera di Padova
Sponsor class: OTHER
First posted: 2012-07-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing liver transplantation

Brief summary: The purpose of this study is to verify any existing relationship between urinary parameters (such as excretion of sodium, chlorine, urinary partial CO2 pressure \[PuCO2\]) and general volemic indicators (such as PiCCO, ScvO2, O2 delivery) during liver transplant.


Eligibility criteria: Inclusion Criteria:

* surgery for liver transplantation
* age 18-75
* ASA class I-III

Exclusion Criteria:

* age above 75 or under 18
* ASA class IV
* pre-existing renal failure
* pregnant patients
* patients unable to give written consent

Primary outcomes:
measure: Determination of hemodynamic indicators (PiCCO, ScvO2, O2-delivery) and three urinary analytes (sodium, chloride, CO2 partial pressure)
timeFrame: During the stay of the patient in the operating room (in average 8 hours) and the subsequent stay in the post-surgery intensive care unit (in average 5 days)
Secondary outcomes:
Other outcomes:
Locations:
city: Padova
country: Italy
facility: Azienda Ospedaliera di Padova
Study officials:
affiliation: Università degli Studi di Padova - Azienda Ospedaliera di Padova
name: Carlo Ori, Prof. M.D.
role: STUDY_CHAIR
affiliation: Azienda Ospedaliera di Padova
name: Paolo Feltracco, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Azienda Ospedaliera di Padova
name: Andrea Bortolato, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03054116: Airflow Perturbation Device (APD) for the Evaluation of Pulmonary and Sleep Disorders
Official title: Airflow Perturbation Device (APD) for the Evaluation of Pulmonary and Sleep Disorders
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Airway Obstruction
Lead sponsor: Walter Reed National Military Medical Center
Sponsor class: FED
First posted: 2017-02-15
Enrollment: 199
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients referred to the Walter Reed NNMC pulmonary clinic mixed with clinically normal volunteers.

Brief summary: In a prospective, observational study the investigators compared resistance values measured using the airway perturbation device (APD) to impulse oscillometry and spirometry. The investigators also created reference equations for normal APD resistance ranges using the data from clinically normal volunteers.


Eligibility criteria: Inclusion Criteria:

* Male and female subjects \> 18 years
* Referred for PFTs and/or PSG at WRNMMC
* All races and ethnicities will be included
* Pregnant women will be included

Exclusion Criteria:

* \< 18 years of age
* If mental status is questionable, the patient will be excluded at the discretion of the consenting provider
* Unable/unwilling to follow the directions necessary for APD use

Primary outcomes:
measure: Number of participants with APD correlation > 0.5 with spirometry
timeFrame: At enrollment
Secondary outcomes:
measure: Number of participants with APD correlation > 0.5 with impulse oscillometry
timeFrame: At enrollment
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01843816: The Effect of Body Shape on Tragus-Wall Measurement
Official title: The Effect of Body Shape on Tragus-Wall Measurement
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obesity
Keywords: Tragus-to-wall distance
obesity
body shape
height
weight
Lead sponsor: Vakif Gureba Training and Research Hospital
Sponsor class: OTHER
First posted: 2013-05-01
Enrollment: 465
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy subjects between 18-65 ages who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)

Brief summary: Tragus-to-wall distance (TWD) measurements is a method to evaluate spinal mobility in ankylosing spondylitis (AS) patients and it also takes place in Bath Ankylosing Spondylitis Metrology Index (BASMI). Being obese or slim may affect TWD. As well as the person's losing or taking weight may lead wrong evaluations, in comparative studies, according to the height or weight uneven distribution of groups may affect the results. The aim of this study is to investigate whether the body shape affect TWD or not.

Detailed description: Healthy volunteers between 18-65 ages who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)will be included into the study. A wall corner will be used as the measurement platform; the evaluated person will be positioned as described in BASMI. A rigid ruler will be placed form anterior superior iliac spine (SIAS) to the lateral wall, parallel to the back wall; a projection point will be determined and its distance from back wall will be measured (SIAS-WD). In the same position, projection point of the middle of the humerus head and back wall distance (shoulder-WD) and TWD also will be measured. The relationships between these parameters will be statistically assessed.

Eligibility criteria: Inclusion Criteria:

* Volunteers between 18-65 ages

Exclusion Criteria:

* subjects with disorders that may disturb posture or erect position
* inflammatory diseases,
* kyphosis,
* scoliosis,
* joint deformities

Primary outcomes:
measure: The assessment of the effects of having different weight and body shape on Tragus-Wall Measurement
timeFrame: 15 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bezmialem Vakif University
Study officials:
affiliation: Bezmialem Vakif University
name: Nihal Ozaras, Ass.Prof.
role: STUDY_CHAIR
References:
Clinical trial NCT01232816: Role of T Helper 17 and Regulatory T Cells in Delayed Graft Function
Official title: Can T Helper 17 and Regulatory T Cells Explain the Pathophysiology of Delayed Graft Function in Renal Transplant Recipients?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Delayed Graft Function
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
Collaborators: name: Astellas Pharma Canada, Inc.
First posted: 2010-11-02
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All kidney transplant recipients at our institution will be recruited prior to their operative procedure.

Brief summary: Delayed graft function (DGF) increases risk of acute rejection after kidney transplantation (KTx). Interleukin-6, which is produced in DGF, is critical in directing naive T helper cells differentiation towards T helper 17 (Th17) and away from regulatory T (Treg) cells. The investigators hypothesize there is an increase in Th17 and a decrease in Treg expression in KTx recipients with DGF compared to those without, leading to immunologic consequences. The investigators will test their hypothesis by measuring in both groups expression of Th17, Treg, and related cytokines in blood, urine, kidney biopsy, and kidney preservation fluid, and correlating these results with immunologic events.

Detailed description: All adult recipients of a primary kidney transplant will be eligible. Subjects will have blood samples drawn from which we will isolate lymphocytes and analyze the Treg population based on surface markers as well as a functional assay. The measures of Treg function will be compared to outcomes including DGF, graft survival and graft function, as well as the development of immunological complications such as donor-specific antibody production, acute rejection, IFTA and opportunistic infection.

Eligibility criteria: Inclusion Criteria:

* Kidney transplant recipients

Exclusion Criteria:

* None

Primary outcomes:
measure: Graft function
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: McGill University Health Center
state: Quebec
Study officials:
affiliation: McGill University Health Centre/Research Institute of the McGill University Health Centre
name: Steven Paraskevas, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nguyen MT, Fryml E, Sahakian SK, Liu S, Cantarovich M, Lipman M, Tchervenkov JI, Paraskevas S. Pretransplant Recipient Circulating CD4+CD127lo/- Tumor Necrosis Factor Receptor 2+ Regulatory T Cells: A Surrogate of Regulatory T Cell-Suppressive Function and Predictor of Delayed and Slow Graft Function After Kidney Transplantation. Transplantation. 2016 Feb;100(2):314-24. doi: 10.1097/TP.0000000000000942.
Clinical trial NCT05901116: The Efficacy of SPSIPB on Postoperative Pain in Patients Undergoing Reduction Mammoplasty Surgery: Case Series
Official title: The Efficacy of Serratus Posterior Superior Intercostal Plane Block (SPSIPB) on Postoperative Pain and Total Analgesic Consumption in Patients Undergoing Reduction Mammoplasty Surgery: Case Series
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post Operative Pain
Keywords: serratus posterior superior intercostal plane block
postoperative pain
reduction mammoplasty
regional anesthesia
Lead sponsor: Cumhuriyet University
Sponsor class: OTHER
First posted: 2023-06-13
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The aim of this study is to investigate the postoperative analgesic efficacy of SPSIPB and its effect on opioid consumption in patients undergoing reduction mammoplasty.

Detailed description: Ten patients had serratus posterior superior intercostal plane block (SPSIPB) as the intervention. Patients had SPSIPB with 0.25% bupivacaine (total volume of 30 ml) before the surgery in operating room. Numerical rating scale (NRS) was used to assess postoperative pain on 1st, 6th, 12th and 24th hour after the surgery. Total tramadol consumption was calculated by using patient-controlled analgesia (PCA) device. Patient satisfaction was assessed by using quality of recovery-15 (QoR15) scale. Paracetamol was planned as resque analgesic drug (maximum dose: 3 gr/day).

Eligibility criteria: Inclusion Criteria:

* Adult patients older than 18 years of age who underwent reduction mammoplasty under general anesthesia and are American Society of Anesthesiologists (ASA) I-II-III according to the ASA risk classification.

Exclusion Criteria:

* Patients who did not give consent,
* patients with coagulopathy,
* patients with signs of infection at the block application site,
* patients using anticoagulants,
* patients with local anesthetic drug allergies,
* patients with unstable hemodynamics,
* patients who could not cooperate during postoperative pain assessment

Primary outcomes:
measure: Numerical rating scale (NRS) scores
timeFrame: Postoperative 24 hours
measure: Total Tramadol consumption
timeFrame: Postoperative 24 hours
Secondary outcomes:
measure: Resque analgesic need
timeFrame: Postoperative 24 hours
measure: Quality of Recovery scores
timeFrame: Postoperative 24 hours
Other outcomes:
Locations:
city: Sivas
country: Turkey
facility: Sivas Cumhuriyet University
Study officials:
affiliation: Sivas Cumhuriyet University School of Medicine, Anesthesiology and Reanimation
name: Oğuz Gündoğdu
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tulgar S, Ciftci B, Ahiskalioglu A, Bilal B, Sakul BU, Korkmaz AO, Bozkurt NN, De Cassai A, Torres AJ, Elsharkawy H, Alici HA. Serratus Posterior Superior Intercostal Plane Block: A Technical Report on the Description of a Novel Periparavertebral Block for Thoracic Pain. Cureus. 2023 Feb 3;15(2):e34582. doi: 10.7759/cureus.34582. eCollection 2023 Feb.
Clinical trial NCT06469216: Efficacy of Hyaluronic Acid in Prevention of Acute Radiation Proctitis
Official title: Efficacy of Hyaluronic Acid in Prevention of Acute Radiation Proctitis: Multi-center, Double-blind, Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Acute Radiation Proctitis
Acute Radiation Enteritis
Keywords: double blind
placebo control
Randomized Clinical Trial
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-06-21
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A randomized placebo-controlled clinical trial to evaluate efficacy of hyaluronic acid in prevention of acute radiation proctitis among oncology patient population especially who are diagnosed with abdomeno-pelvic tumors and subsequently required radiotherapy.


Eligibility criteria: Inclusion Criteria:

* All patients diagnosed with pelvic or gastrointestinal malignancies (tumors in uterus, cervix, prostate, seminal vesicles, kidney, colon, etc.),
* All patients who required adjuvant or radical radiation therapy;
* Age \&lt; 80 years;
* Karnofsky Performance Status ≥ 60

Exclusion Criteria:

* Patients were excluded if they had

  * gt; previous pelvic radiotherapy,
  * gt; inflammatory bowel disease or
  * gt; rectal issues (e.g., haemorrhoids).
* Patients diagnosed with cancer rectum

Primary outcomes:
measure: Time (in days) to occurrence of Acute Radiation Proctitis
timeFrame: for each patient: time from the first day of radiation therapy for up to 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Zagazig
country: Egypt
facility: Al-Ahrar teaching hospital
state: Sharqia
city: Cairo
country: Egypt
facility: Ahmed Maher teaching hospitals
Study officials:
References:
Clinical trial NCT04993716: Epidemiological Study on the Management of Out-of-hospital Cardiac Arrest Survivors in Champagne ArDEnnes
Official title: Epidemiological Study on the Management of Out-of-hospital Cardiac Arrest Survivors in Champagne ArDEnnes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Out-of-hospital Cardiac Arrest
Lead sponsor: Centre Hospitalier de Troyes
Sponsor class: OTHER
First posted: 2021-08-06
Enrollment: 294
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Our participants must be the victim of an ACEH on the Champagne-Ardenne territory admitted living in the hospital and be over eighteen years old

Brief summary: Out-of-hospital cardiac arrest (OHCA) is a public health problem, affecting 50,000 people per year in France. Intervention time (initiation of cardiopulmonary resuscitation (CPR) and advanced CPR) are associated with a better prognosis. Despite this, the latest published data show a very low overall survival (5%). Our territory has only three centers distributed hospitals with both a 24-hour coronary angiography platform and an intensive care unit. Finally, although 60% of ACEHs receive coronary angiography in the Île de France region, it is performed on only 15% of patients in the Reims University Hospital.

Therefore, it seems essential to conduct a study on the reality of the support of ACEH and to study the clinical and biological factors as well as the influence of the geographical distribution of specialized technical platforms on the prognosis of patients.


Eligibility criteria: Inclusion Criteria:

* Patient victim of ACEH in the Champagne-Ardenne region admitted living in hospital.

Exclusion Criteria:

* patient under the age of 18

Primary outcomes:
measure: Analysis of prognostic factors associated with survival without severe neurological sequelae (CPC 1-2) at 3 months among the following variables
timeFrame: 3 months
measure: Analysis of prognostic factors associated with survival without severe neurological sequelae (CPC 1-2) with collection of a bank of biological samples, identification of clinical factors and targeted temperature control
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Troyes
country: France
facility: hospital center of Troyes
state: Champagne Ardennes
Study officials:
References:
Clinical trial NCT02691416: Role of Propofol Postconditioning on Oxidative Stress and Cognitive Function
Official title: Role of Propofol Postconditioning on Oxidative Stress and Cognitive Function in Patients Undergoing Intracranial Aneurysm Surgery.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cerebral Arterial Aneurysm
Lead sponsor: The Third Central Clinical College of Tianjin Medical University
Sponsor class: OTHER
First posted: 2016-02-25
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study was to evaluate differences between propofol postconditioning and sevoflurane anesthesia in the intracranial aneurysm surgery about antioxidant effect.

Detailed description: intracranial aneurysm surgery may lead to regional ischemic reperfusion injury. Propofol, as an antioxidative phenol, has been demonstrated that mitigate the brain I/R in rats.

As for sevoflurane, some investigation indicated that sevoflurane is able to reduce oxidative stress in cell(except neuronal cell lines ) and rodent models, but the antioxidant effect did not found in human minor incision surgeries, furthermore, oxidative stress was raised in the major surgeries including orthopedic surgeries, hysterectomy, cholecystectomy, and thoracotomy

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis intracranial aneurysm surgery ,
* American Society of Anesthesiologists (ASA)Ⅰ-Ⅱ.

Exclusion Criteria:

* severe hepatic and renal dysfunction
* coagulation disorder
* taking antioxidant perioperative period

Primary outcomes:
measure: Evidences of Clinically Definite Oxidative Stress Confirmed by ELISA Kit
timeFrame: before induction,after clamping removal ,operation ending ,1,3,7days post surgery
measure: Evidences of Clinically Definite Oxidative Stress Confirmed by ELISA
timeFrame: before induction, after clamping removal,operation ending,1,3,7days post surgery
measure: Evidences of Clinically Definite Oxidative Stress:Micronuclei
timeFrame: before induction,clamping removal ,operation ending,1,3,7days post surgery
measure: Evidences of Clinically Definite Oxidative Stress Confirmed by High Performance Liquid Chromatography
timeFrame: before induction,after clamping removal ,operation ending ,1,3,7days post surgery
measure: Evidences of Clinically Definite Oxidative Stress: Nuclear Buds
timeFrame: before induction,clamping removal ,operation ending,1,3,7days post surgery
measure: Evidences of Clinically Definite Oxidative Stress: Nucleoplasmic Bridges
timeFrame: before induction,clamping removal ,operation ending,1,3,7days post surgery
Secondary outcomes:
measure: Mini Mental State Examination (MMSE)
timeFrame: before induction,1,3,7days post surgery
measure: Montreal Cognitive Assessment (MoCA)
timeFrame: before induction,1,3,7days post surgery
Other outcomes:
Locations:
Study officials:
affiliation: The Third Central Clinical College of Tianjin Medical University
name: Haiyun Wang
role: STUDY_DIRECTOR
References:
Clinical trial NCT00333216: Anecortave Acetate Risk-Reduction Trial (AART)
Official title: Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: AMD
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2006-06-02
Enrollment: 24
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.


Eligibility criteria: Inclusion Criteria:

* Dry AMD in study eye, Wet AMD in non-study eye;
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Under 50;
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Proportion of patients with sight-threatening CNV in study eye
timeFrame: Month 48
Secondary outcomes:
measure: Time to development of sight-threatening CNV
timeFrame: Up to 48 months
measure: Proportion of patients with stable vision
timeFrame: Up to 48 months
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Contact Alcon Call Center for Trial Locations
state: Texas
Study officials:
affiliation: Study Director
name: Terry Wiernas, PhD
role: STUDY_DIRECTOR
References: